Skip to content

The effect of virtual reality in the treatment of addiction

Investigating the effect of aversive therapy using virtual reality on drug craving, depression and self-efficacy in patients under methadone maintenance treatment `

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20240429061588N1
Enrollment
99
Registered
2024-05-01
Start date
2024-05-21
Completion date
Unknown
Last updated
2024-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Substance Use disorder.

Interventions

Intervention 1: Intervention group: 33 study intervention participants are justified for a period of 12 weeks not to change their normal physical and nutritional activities during this period of study

Sponsors

Pardis International University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
25 Years to 55 Years

Inclusion criteria

Inclusion criteria: Clients should visit the clinic at least once a week Age 25 to 55 years Clients are on a fixed dose of methadone maintenance treatment for at least 3 months or more Clients are willing to participate in the project and complete the treatment consent form Have at least reading and writing literacy Have the ability to speak and communicate Absence of severe vision and hearing problems Absence of severe and frequent headaches No history of mental illness, epilepsy and malignant diseases Do not have any type of phobia Do not suffer from the symptoms of stimulant use and drug poisoning Not under the treatment of a psychiatrist for all kinds of cognitive and psychosomatic disorders

Exclusion criteria

Exclusion criteria: Unwillingness to cooperate at any stage of the plan Urine test for morphine, amphetamine and hashish is checked three times for each person during the study, and if the test is positive, the person is excluded from the study. Having psychotic symptoms Pregnant women Use of special psychiatric or neurological drugs affecting cognition, such as antipsychotics

Design outcomes

Primary

MeasureTime frame
DDQ momentary consumption craving measurement - in the consumption craving questionnaire, the number 0 indicates the absence of an experience or feeling and the number 5 indicates the maximum presence of an experience or feeling. Timepoint: 12 weeks. Method of measurement: All people who enter the study, in addition to the demographic questionnaire, the momentary craving measurement questionnaire (DDQ); Bramson addiction withdrawal self-efficacy questionnaire; Beck depression questionnaire; They are completed and measured once before entering the study and once after 12 weeks of study. The virtual reality intervention was done once a week for about 6 minutes for the people who entered this part of the study; And the exams and the process of increasing or decreasing the points are finally checked and compared. In this way, the score of each person subjected to instrumental intervention is known at the end of each week, and it is announced to them.

Secondary

MeasureTime frame
It has no variable consequences. Timepoint: They are completed and evaluated once before entering the study and once after 12 weeks of the study. Method of measurement: Beck Depression Inventory (BDI) This questionnaire, which contains 21 questions, was created by Beck et al. in order to measure the feedback and symptoms of depressed patients. The drug was designed and used by Bramson (1999), it consists of 16 questions. According to Bramson's instructions regarding how to score, the answers were determined in the form of seven options and using a Likert scale (one point for each scale) as follows: 1-definitely no 2-probably no 3-maybe no 4- I can't say 5-Maybe yes 6-Possibly yes 7-Definitely yes The score range of this questionnaire was between 16 and 112.Scores are measured and compared once before the start of the study and once after 12 weeks.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFateme Sadat Ghoreishi

Kashan University of Medical Sciences

z.ghoreishi@yahoo.com+98 31 5558 9212

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026